XERIS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 248.12K shares, a 21.41% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 259.94K shares, a 80.98% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 129.93K shares, a 566.88% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 1.18M shares.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.99M shares, a 1102.05% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 248.90K shares, a 1673.30% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 14.04K shares, a 25.01% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 11.23K shares, a 87.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 248.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.82M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 259.94K shares 10-Q · filed 2026-05-07 | 1.89M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 129.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 2.99M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 1.18M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 2.88M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 315.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.70M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.37M shares 10-Q · filed 2025-05-08 | 1.39M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 19.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 248.90K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 229.42K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 229.42K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | 229.42K shares 10-Q · filed 2024-05-09 | 243.45K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 14.04K shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 14.04K shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-06-30 | 14.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 14.04K shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | 0.00 shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | 11.23K shares 10-K · filed 2024-03-06 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | |
| 2022-03-31 | 11.23K shares 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 93.40K shares 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |